The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome

@article{Storr2008TheRO,
  title={The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome},
  author={Martin A. Storr and Birol Y{\"u}ce and Christopher N. Andrews and Keith A. Sharkey},
  journal={Neurogastroenterology \& Motility},
  year={2008},
  volume={20}
}
Abstract  Irritable bowel syndrome (IBS) is a spectrum of disorders characterized by abdominal discomfort and pain, associated with altered bowel habits. Though gut motility, secretion and sensation may be altered in patients with IBS, the pathophysiology of this condition remains to be fully understood. The endocannabinoid system is involved in the regulation of numerous gastrointestinal functions including motility, sensation and secretion under both physiological and pathophysiological… Expand
Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy.
TLDR
The importance of the Endocannabinoid system, its connections with the normal gastrointestinal functions and abnormalities like IBS, and the role of cannabis as medical therapy in IBS patients are highlighted. Expand
Gut feelings about the endocannabinoid system
  • V. Di Marzo, F. Piscitelli
  • Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2011
TLDR
Novel data highlight the multi‐faceted aspects of endocannabinoid function in the GI tract, support the feasibility of the future therapeutic exploitation of this signaling system for the treatment of GI disorders, and leave space for some intriguing new hypotheses on the role ofendocannabinoids in the gut. Expand
Novel strategies and future landmarks in the treatment of irritable bowel syndrome
TLDR
A pathogenesis-based overview of recently developed pharmaceutics and future perspectives on the pathogenesis of IBS is provided and a good safety profile is of primary importance in the treatment of functional gastrointestinal disorders. Expand
Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment.
TLDR
Current and emerging therapies in IBS are reviewed based upon IBS as a serotonergic disorder; stimulating intestinal chloride channels; modulation of visceral hypersensitivity; altering low-grade intestinal inflammation; and modulation of the gut microbiota. Expand
Cannabinoids and the gut: new developments and emerging concepts.
TLDR
Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric infections and inflammatory conditions to disorders of motility, emesis and abdominal pain, with recent data on genetic mutations in the endocannabinoid system in GI disease highlighted. Expand
Novel insights which may translate into treatments for irritable bowel syndrome
  • A. Izzo
  • Medicine
  • Front. Pharmacol.
  • 2013
TLDR
Frontiers in Pharmacology brings together a group of review and original articles focusing on IBS to suggest that a pharmacological modulation of TLRs, by controlling the abnormal kynurenine pathway, be a novel potential strategy for IBS and the use of plasma tryptophan metabolites assay as a biomarker for Ibs diagnosis. Expand
Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.
  • F. Chang
  • Medicine
  • World journal of gastroenterology
  • 2014
TLDR
IBS is a heterogeneous disorder with multidimensional pathogeneses and personalized medicines with multidisciplinary approaches using different classes of drugs, psychiatric measures, probiotics and antibiotics, dietary therapy, and finally CAMs, can be considered. Expand
Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet
TLDR
The present data suggest that CB receptors represent one of the molecular pathways through which the KD works and support possible cannabinoid-mediated protection at the intestinal level in the IBS rats after dietary treatment. Expand
Cannabinoid pharmacology and therapy in gut disorders
TLDR
This review summarizes the main recent findings on the role of cannabinoid receptors, their synthetic or natural ligands and their metabolizing enzymes in normal gastrointestinal function and in disorders including irritable bowel syndrome, inflammatory bowel disease, colon cancer and gastrointestinal chemotherapy‐induced adverse effects. Expand
Review: The Role of Cannabinoids on Esophageal Function—What We Know Thus Far
TLDR
The current understanding of the ECS role in various esophageal functions and disorders is presented and new therapeutic modalities that may help advance current treatment options are presented. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 139 REFERENCES
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract
TLDR
An alternative and promising avenue for therapeutic applications resides in the treatment with CB1 receptor agonists that are unable to cross the blood–brain barrier, or with compounds that inhibit the degradation of endogenous ligands (endocannabinoids) of CB1 receptors, hence prolonging the activity of the endocannabinoid system. Expand
A role for inflammation in irritable bowel syndrome?
TLDR
Human and animal studies support the concept that inflammation may perturb gastrointestinal reflexes and activate the visceral sensory system even when the inflammatory response is minimal and confined to the mucosa. Expand
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation
TLDR
This review of the current knowledge of CB2 receptors in the gastrointestinal tract highlights its role in regulating abnormal motility, modulating intestinal inflammation and limiting visceral sensitivity and pain. Expand
Mechanisms of hypersensitivity in IBS and functional disorders
  • F. Azpiroz, M. Bouin, +4 authors R. Spiller
  • Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2007
TLDR
This article addresses the proposed mechanisms leading to hypersensitivity: from genetic to inflammatory disorders, from central to peripheral alterations of function, and the peripheral and central mechanisms involved and the role of inflammation on hypersensitivity. Expand
Involvement of cannabinoid receptors in gut motility and visceral perception
TLDR
The challenge is to accomplish CBR activation while minimizing adverse effects and abuse liabilities, and some recent evidence with inhibitors of EC uptake and metabolism suggest that these could be exploited for therapeutic gain. Expand
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats
TLDR
Investigating whether this upregulation is a marker also of celiac disease-induced atrophy found intestinal endocannabinoid levels peak with atrophy and regress with remission in both celiac patients and methotrexate-treated rats suggests the latter might be used as a model to study the role of the endoc cannabinoidoid system in celiac Disease. Expand
IBS: a syndrome or many diseases?
  • G. Holtmann
  • Medicine
  • Best practice & research. Clinical gastroenterology
  • 2004
TLDR
It is reasonable to anticipate that IBS will be dissected accordingly and disease concepts will accept the irritable bowel syndrome as the clinical manifestation of a number of different disorders. Expand
Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
TLDR
Migraine, fibromyalgia, IBS and related conditions display common clinical, biochemical and pathophysiological patterns that suggest an underlying clinical endocannabinoid deficiency that may be suitably treated with cannabinoid medicines. Expand
Endocannabinoids and the gut.
In the digestive tract, there is evidence for the presence of high amounts of endocannabinoids (anandamide and 2-arachidonylglycerol) and of mechanisms for endocannabinoid metabolism and possiblyExpand
Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation.
TLDR
The hypothesis that cannabinoid mechanisms may play a role in the control of colonic motility in humans and deserve further study supports the hypothesis of genetic variation in metabolism of endocannabinoids with symptom phenotype in D- IBS and M-IBS and with faster colonic transit in D.IBS. Expand
...
1
2
3
4
5
...